Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this research study is to explore ways to improve motor, cognitive and immune functions for aging adults using multiple techniques like lifestyle changes and risk factor management, as well as medications and supplements believed to have a positive effect on health.
The goal in this pilot open-label study is to conduct a feasibility test of a multi-component, personalized intervention designed to improve the aging human healthspan. The trial will recruit at least 20 adults aged 50-70, both male and female. The total time of study participation is up to 5 months.
The intervention will last for approximately 3 months, with testing of motor, cognitive, and immune outcomes before and after the intervention.
The intervention consist of three components:
The outcome assessments will be measured both pre- and post-intervention and up to three times at each time point. These assessments will look at biomarkers related to aging. Assessments will include strength and endurance tests, validated neuropsychological tests, and a blood drawn to look at immune function.
An MRI scan will also be offered to participants who are able to undergo the scan to look at brain health and aging, both pre- and post-intervention.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Behavioral lifestyle management plus dasatinib, quercetin and vortioxetine | Experimental | Open label multicomponent, personalized intervention incorporating behavioral and medicinal therapies |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Risk managment | Behavioral | Behavioral lifestyle changes including an exercise program, healthy eating recommendations, reviewing medical management for cardiometabolic risk conditions, deprescribing review for brain toxic meds, online cognitive training, as well as recommendations to improve sleep quality, or smoking cessation as needed |
| Measure | Description | Time Frame |
|---|---|---|
| Number of participants who completed the outcome measure assessments and intervention | Reviewing feasibility outcomes including recruitment, retention, participant adherence, interventionist fidelity to behavioral treament protocols and collection of outcome measures. | 5 months |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Motor function | Endurance capacity; 6 Minute Walking Test Lower body power: Leg dynamometer Skeletal muscle: D3 creatine dilution | 5 months |
| Cognitive Function | NIH Toolbox Cognitive Battery, Fluid Cognition Composite. Each of the 5 subscales have a mean of 100 with a standard deviation of 15. |
Participants must be residents of Illinois or Missouri and able to come to St. Louis offices in person.
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Eric Lenze, MD | Washington University School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | United States |
Contact PI
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Dasatinib | Drug | dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial |
|
|
| Quercetin (dietary supplement) | Dietary Supplement | e intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial |
|
|
| Vortioxetine | Drug | Participants will be prescribed vortioxetine to take daily, in combination with online cognitive training |
|
|
| 5 months |
| Immune Function | Blood draws to look at biomarkers related to immune function | 5 months |
| ID | Term |
|---|---|
| D060825 | Cognitive Dysfunction |
| D057185 | Sedentary Behavior |
| ID | Term |
|---|---|
| D003072 | Cognition Disorders |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069439 | Dasatinib |
| D011794 | Quercetin |
| D019587 | Dietary Supplements |
| D000078784 | Vortioxetine |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |
| D044948 | Flavonols |
| D005419 | Flavonoids |
| D002867 | Chromones |
| D001578 | Benzopyrans |
| D011714 | Pyrans |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
| D010879 | Piperazines |
Not provided
Not provided